Back to News
Market Impact: 0.35
Neuronetics Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Neuronetics (NASDAQ: STIM) reported revenue growth and a wider gross margin in the third quarter of 2026, returning to positive adjusted EBITDA. The company attributed performance to record NeuroStar system sales and continued revenue-cycle improvements across its Greenbrook clinic network.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
STIM0.75
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss